Literature DB >> 29140820

Renal effects of cytokines in hypertension.

Yi Wen1,2, Steven D Crowley1.   

Abstract

PURPOSE OF REVIEW: Inflammatory cytokines contribute to the pathogenesis of hypertension through effects on renal blood flow and sodium handling. This review will update recent advances that explore the renal actions of immune cells and cytokines in the pathogenesis of hypertension. RECENT
FINDINGS: Populations of cells from both the innate and adaptive immune systems contribute to hypertension by modulating functions of the vasculature and epithelial cells in the kidney. Macrophages and T lymphocytes can directly regulate the hypertensive response and consequent target organ damage. Dendritic cells and B lymphocytes can alter blood pressure (BP) indirectly by facilitating T-cell activation. Proinflammatory cytokines, including tumor necrosis factor-α, interleukin 17, interleukin 1, and interferon-γ augment BP and/or renal injury when produced by T helper 1 cells, T helper 17 cells, and macrophages. In contrast, interleukin 10 improves vascular and renal functions in preclinical hypertension studies. The effects of transforming growth factor-β are complex because of its profibrotic and immunosuppressive functions that also depend on the localization and concentration of this pleiotropic cytokine.
SUMMARY: Preclinical studies point to a key role for cytokines in hypertension via their actions in the kidney. Consistent with this notion, anti-inflammatory therapies can attenuate BP elevation in human patients with rheumatologic disease. Conversely, impaired natriuresis may further polarize both T lymphocytes and macrophages toward a proinflammatory state, in a pathogenic, feed-forward loop of immune activation and BP elevation. Understanding the precise renal actions of cytokines in hypertension will be necessary to inhibit cytokine-dependent hypertensive responses while preserving systemic immunity and tumor surveillance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29140820      PMCID: PMC5792304          DOI: 10.1097/MNH.0000000000000385

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  92 in total

Review 1.  Under pressure: the search for the essential mechanisms of hypertension.

Authors:  Thomas M Coffman
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Renoprotective effects of anti-TGF-β antibody and antihypertensive therapies in Dahl S rats.

Authors:  Sydney R Murphy; Annette J Dahly-Vernon; Kathryn M J Dunn; Chun Cheng Andy Chen; Steven R Ledbetter; Jan M Williams; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-04-25       Impact factor: 3.619

3.  Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice.

Authors:  Modar Kassan; Maria Galan; Megan Partyka; Mohamed Trebak; Khalid Matrougui
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

4.  Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension.

Authors:  Antony Vinh; Wei Chen; Yelena Blinder; Daiana Weiss; W Robert Taylor; Jörg J Goronzy; Cornelia M Weyand; David G Harrison; Tomasz J Guzik
Journal:  Circulation       Date:  2010-11-29       Impact factor: 29.690

5.  γδ T Cells Mediate Angiotensin II-Induced Hypertension and Vascular Injury.

Authors:  Antoine Caillon; Muhammad Oneeb Rehman Mian; Julio C Fraulob-Aquino; Ku-Geng Huo; Tlili Barhoumi; Sofiane Ouerd; Peter R Sinnaeve; Pierre Paradis; Ernesto L Schiffrin
Journal:  Circulation       Date:  2017-03-22       Impact factor: 29.690

6.  Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats.

Authors:  M Gómez-Chiarri; A Ortíz; J L Lerma; M J López-Armada; F Mampaso; E González; J Egido
Journal:  Lab Invest       Date:  1994-04       Impact factor: 5.662

7.  Antihypertensive effects of chronic anti-TGF-beta antibody therapy in Dahl S rats.

Authors:  Annette J Dahly; Kimberly M Hoagland; Averia K Flasch; Sharda Jha; Steven R Ledbetter; Richard J Roman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-09       Impact factor: 3.619

8.  Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy.

Authors:  Srinivas Sriramula; Masudul Haque; Dewan S A Majid; Joseph Francis
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Chemokine receptor 2b inhibition provides renal protection in angiotensin II - salt hypertension.

Authors:  Ahmed A Elmarakby; Jeffrey E Quigley; Jeffrey J Olearczyk; Aarthi Sridhar; Anthony K Cook; Edward W Inscho; David M Pollock; John D Imig
Journal:  Hypertension       Date:  2007-10-15       Impact factor: 10.190

10.  Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants.

Authors: 
Journal:  Lancet       Date:  2016-11-16       Impact factor: 79.321

View more
  4 in total

1.  Interleukin 17A Participates in Renal Inflammation Associated to Experimental and Human Hypertension.

Authors:  Macarena Orejudo; Raul R Rodrigues-Diez; Raquel Rodrigues-Diez; Ana Garcia-Redondo; Laura Santos-Sánchez; Javier Rández-Garbayo; Pablo Cannata-Ortiz; Adrian M Ramos; Alberto Ortiz; Rafael Selgas; Sergio Mezzano; Carolina Lavoz; Marta Ruiz-Ortega
Journal:  Front Pharmacol       Date:  2019-09-13       Impact factor: 5.810

Review 2.  Current Understanding of Pressure Natriuresis.

Authors:  Eun Ji Baek; Sejoong Kim
Journal:  Electrolyte Blood Press       Date:  2021-12-23

3.  Inflammatory cytokines are associated to lower glomerular filtration rate in patients with hypertensive crisis.

Authors:  Days O Andrade; Franciana L Aguiar; Ana Luiza P Mansor; Flavia M Valente; Doroteia R S Souza; Valquiria da Silva Lopes; Leticia B Fernandes; Moacir F Godoy; Juan C Yugar-Toledo; Luciana N Cosenso-Martin; Jose F Vilela-Martin
Journal:  Front Cardiovasc Med       Date:  2022-09-29

4.  Ixekizumab May Improve Renal Function in Psoriasis.

Authors:  Giuseppe Fabrizio Amoruso; Steven Paul Nisticò; Luigi Iannone; Emilio Russo; Giuseppe Rago; Cataldo Patruno; Luigi Bennardo
Journal:  Healthcare (Basel)       Date:  2021-05-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.